Epacadostat clinical trials
Also written INCB024360.
ClinicalTrials.gov finds 61 studies for epacadostat. How that becomes 57 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives epacadostat. Its counts are asked again every night. How drug pages count
- 61Found by its intervention search · See all 61 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 60 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNCT07490002 · A title error; the arms give iparomlimab and tuvonralimabReport a problem
- 60Give epacadostat to participants
- −3Give it beside what is tested
- 57Test it: the count on this site
Get an email when these change. Save the epacadostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
57 studies that test it; most in 2018 (19)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 19 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 32
Incyte Corporation (22) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of Chicago (3) · Washington University School of Medicine (2) · Roswell Park Cancer Institute (2) · City of Hope Medical Center (2) · Insel Gruppe AG, University Hospital Bern (2)
Often tested with
Tested in the same studies.
Retifanlimab (3) · Cyclophosphamide (2) · Tuparstobart (2) · Verzistobart (2) · Parsaclisib (2) · Nivolumab (2) · Pembrolizumab (1) · Bevacizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 4 most studied
New when their studies opened, with epacadostat beside them; studies of each.
Reaching primary completion within a year · 1
Studies that test epacadostat.
- Jul 2027Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerPhase 1/2 · Washington University School of Medicine
Studies
Open first, then newest update. How each study uses epacadostat has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 57
- Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerRecruitingPhase 1/2Washington University School of MedicineNCT03516708Dose found, added to chemoradiation before rectal surgeryWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedPhase 3Incyte CorporationNCT03358472With pembrolizumab against pembrolizumab alone and EXTREMEWritten as EpacadostatHow we knowReport a problem
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedPhase 2Incyte CorporationNCT04463771Added to retifanlimab in two endometrial cancer groupsWritten as epacadostatHow we knowReport a problem
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnPhase 2City of Hope Medical CenterNCT03402880With pembrolizumab in extensive-stage small cell lung cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894With pembrolizumab against sunitinib or pazopanib in kidney cancerWritten as EpacadostatHow we knowReport a problem
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03414229With pembrolizumab across sarcoma subtypesWritten as EpacadostatHow we knowReport a problem
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedPhase 1/2Incyte CorporationNCT01604889Rising doses added to ipilimumab in melanomaWritten as EpacadostatHow we knowReport a problem
- A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedPhase 1Incyte CorporationNCT02298153Rising doses with atezolizumab in lung and urothelial cancerWritten as EpacadostatHow we knowReport a problem
- Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasCompletedPhase 2Washington University School of MedicineNCT03532295Added to retifanlimab, radiotherapy and bevacizumab in gliomaWritten as EpacadostatHow we knowReport a problem
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedPhase 2Incyte CorporationNCT04586244Alone or with retifanlimab before cystectomyWritten as epacadostatHow we knowReport a problem
- Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedPhase 1/2National Cancer Institute (NCI)NCT03493945Added in one arm to an immunotherapy combination in prostate cancerWritten as EpacadostatHow we knowReport a problem
- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedPhase 3Incyte CorporationNCT02752074Added to pembrolizumab against placebo in melanomaWritten as pembrolizumab + epacadostatHow we knowReport a problem
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)CompletedPhase 3Incyte CorporationNCT03361865Added to pembrolizumab in cisplatin-ineligible urothelial cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)CompletedPhase 2Incyte CorporationNCT03322540Added to pembrolizumab against placebo in PD-L1-high lung cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaCompletedPhase 3Incyte CorporationNCT03374488Added to pembrolizumab after platinum in urothelial cancerWritten as EpacadostatHow we knowReport a problem
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedPhase 1/2Incyte CorporationNCT02327078Dose escalated with nivolumab, with or without chemotherapyWritten as EpacadostatHow we knowReport a problem
- Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedEarly Phase 1National Cancer Institute (NCI)NCT02042430Before surgery, for its immune effect in ovarian cancerWritten as EpacadostatHow we knowReport a problem
- Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03006302Dose found with pembrolizumab and CRS-207 in pancreatic cancerWritten as EpacadostatHow we knowReport a problem
- Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedPhase 2National Cancer Institute (NCI)NCT03602586With pembrolizumab in recurrent clear cell ovarian cancerWritten as EpacadostatHow we knowReport a problem
- Epacadostat and Pembrolizumab in Patients With GISTTerminatedPhase 2Columbia UniversityNCT03291054With pembrolizumab in imatinib-refractory GISTWritten as EpacadostatHow we knowReport a problem
See all 57 studies that test epacadostat →
Tested on its own · 4 — no other medicine in its arm
- Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedEarly Phase 1National Cancer Institute (NCI)NCT02042430Before surgery, for its immune effect in ovarian cancerWritten as EpacadostatHow we knowReport a problem
- A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor MalignanciesTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03471286Before surgery, to see its effect on the tumourWritten as EpacadostatHow we knowReport a problem
- A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedPhase 1Incyte CorporationNCT01195311First-in-human dose escalation in advanced cancersWritten as INCB024360How we knowReport a problem
- Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)CompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT01822691Alone in myelodysplastic syndromesWritten as INCB024360How we knowReport a problem
Tested with established drugs · 34 — they are given beside it
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnPhase 2City of Hope Medical CenterNCT03402880With pembrolizumab in extensive-stage small cell lung cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894With pembrolizumab against sunitinib or pazopanib in kidney cancerWritten as EpacadostatHow we knowReport a problem
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03414229With pembrolizumab across sarcoma subtypesWritten as EpacadostatHow we knowReport a problem
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedPhase 1/2Incyte CorporationNCT01604889Rising doses added to ipilimumab in melanomaWritten as EpacadostatHow we knowReport a problem
- A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedPhase 1Incyte CorporationNCT02298153Rising doses with atezolizumab in lung and urothelial cancerWritten as EpacadostatHow we knowReport a problem
- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedPhase 3Incyte CorporationNCT02752074Added to pembrolizumab against placebo in melanomaWritten as pembrolizumab + epacadostatHow we knowReport a problem
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)CompletedPhase 3Incyte CorporationNCT03361865Added to pembrolizumab in cisplatin-ineligible urothelial cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)CompletedPhase 2Incyte CorporationNCT03322540Added to pembrolizumab against placebo in PD-L1-high lung cancerWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaCompletedPhase 3Incyte CorporationNCT03374488Added to pembrolizumab after platinum in urothelial cancerWritten as EpacadostatHow we knowReport a problem
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedPhase 1/2Incyte CorporationNCT02327078Dose escalated with nivolumab, with or without chemotherapyWritten as EpacadostatHow we knowReport a problem
- Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedPhase 2National Cancer Institute (NCI)NCT03602586With pembrolizumab in recurrent clear cell ovarian cancerWritten as EpacadostatHow we knowReport a problem
- Epacadostat and Pembrolizumab in Patients With GISTTerminatedPhase 2Columbia UniversityNCT03291054With pembrolizumab in imatinib-refractory GISTWritten as EpacadostatHow we knowReport a problem
- Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric CancerCompletedPhase 2George Albert FisherNCT03196232With pembrolizumab in gastric and junction cancerWritten as EpacadostatHow we knowReport a problem
- Epacadostat (INCB24360) in Combination With Sirolimus in Advanced MalignancyActive, not recruitingPhase 1Chao HuangNCT03217669Dose found with sirolimus in advanced cancerWritten as EpacadostatHow we knowReport a problem
- A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)CompletedPhase 1/2Incyte CorporationNCT03085914Dose found with pembrolizumab and seven chemotherapy regimensWritten as EpacadostatHow we knowReport a problem
- Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)CompletedPhase 1Merck Sharp & Dohme LLCNCT02862457Alone and with pembrolizumab, with or without chemotherapyWritten as Epacadostat 25 mgHow we knowReport a problem
- Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnPhase 2City of Hope Medical CenterNCT03592407With pembrolizumab after chemoradiotherapy, before oesophageal surgeryWritten as EpacadostatHow we knowReport a problem
- A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedPhase 1/2Incyte CorporationNCT03347123Dose escalated with nivolumab plus ipilimumab or lirilumabWritten as EpacadostatHow we knowReport a problem
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedPhase 1/2Incyte CorporationNCT02178722Dose escalated with pembrolizumab in selected cancersWritten as INCB024360How we knowReport a problem
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)CompletedPhase 2Incyte CorporationNCT03322566Added to pembrolizumab, with or without chemotherapy, in lung cancerWritten as EpacadostatHow we knowReport a problem
Showing 20 of 34. See all 34 →
Tested in a combination · 19 — another drug in the study is under test too
- Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerRecruitingPhase 1/2Washington University School of MedicineNCT03516708Dose found, added to chemoradiation before rectal surgeryWritten as EpacadostatHow we knowReport a problem
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedPhase 3Incyte CorporationNCT03358472With pembrolizumab against pembrolizumab alone and EXTREMEWritten as EpacadostatHow we knowReport a problem
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedPhase 2Incyte CorporationNCT04463771Added to retifanlimab in two endometrial cancer groupsWritten as epacadostatHow we knowReport a problem
- Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasCompletedPhase 2Washington University School of MedicineNCT03532295Added to retifanlimab, radiotherapy and bevacizumab in gliomaWritten as EpacadostatHow we knowReport a problem
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedPhase 2Incyte CorporationNCT04586244Alone or with retifanlimab before cystectomyWritten as epacadostatHow we knowReport a problem
- Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedPhase 1/2National Cancer Institute (NCI)NCT03493945Added in one arm to an immunotherapy combination in prostate cancerWritten as EpacadostatHow we knowReport a problem
- Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03006302Dose found with pembrolizumab and CRS-207 in pancreatic cancerWritten as EpacadostatHow we knowReport a problem
- Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatTerminatedPhase 2Chase Heaton, MDNCT03823131Added to tavo-EP and pembrolizumab in one head and neck armWritten as EpacadostatHow we knowReport a problem
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionCompletedPhase 1/2Roswell Park Cancer InstituteNCT02166905Added to a NY-ESO-1 vaccine in ovarian cancer remissionWritten as EpacadostatHow we knowReport a problem
- INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedPhase 1Incyte CorporationNCT03589651Dose escalated with retifanlimab in one groupWritten as EpacadostatHow we knowReport a problem
- UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With LymphomaCompletedPhase 1/2University of California, DavisNCT03322384With intralesional SD-101 and radiotherapy in lymphoma and solid tumoursWritten as epacadostatHow we knowReport a problem
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerActive, not recruitingPhase 1/2ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT02785250Added to DPX-Survivac and cyclophosphamide in ovarian cancerWritten as Epacadostat (INCB024360)How we knowReport a problem
- Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03707457Added to nivolumab in one biomarker arm for recurrent glioblastomaHow we knowReport a problem
- Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)WithdrawnPhase 3Incyte CorporationNCT03342352With nivolumab and chemotherapy against EXTREME in head and neckWritten as EpacadostatHow we knowReport a problem
- Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedPhase 1Incyte CorporationNCT02559492With itacitinib in one group of a platform studyWritten as EpacadostatHow we knowReport a problem
- Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerTerminatedPhase 3Incyte CorporationNCT03348904With nivolumab and chemotherapy in first-line lung cancerWritten as EpacadostatHow we knowReport a problem
- Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal CancerTerminatedPhase 1/2Aduro Biotech, Inc.NCT02575807Added to the CRS-207 vaccine in platinum-resistant ovarian cancerWritten as EpacadostatHow we knowReport a problem
- A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyTerminatedPhase 2Incyte CorporationNCT01685255Against tamoxifen after ovarian cancer remissionWritten as EpacadostatHow we knowReport a problem
- Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in RemissionWithdrawnPhase 1/2Roswell Park Cancer InstituteNCT01982487Alone and with a NY-ESO-1 vaccine in ovarian cancer remissionWritten as IDO1 inhibitor INCB024360How we knowReport a problem
Beside a new treatment under test · 3 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with epacadostat: INCB057643 1 · INCB059872 1 · ragifilimab 1 · CB-1158 1
- Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)TerminatedPhase 1/2Incyte CorporationNCT02959437In every armWith pembrolizumab beside new epigenetic agentsWritten as EpacadostatHow we knowReport a problem
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedPhase 1/2Incyte Biosciences International SàrlNCT03277352In every armWith pembrolizumab beside new INCAGN01876Written as EpacadostatHow we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsTerminatedPhase 1/2Incyte CorporationNCT03361228In every armGiven in every arm with new INCB001158Written as EpacadostatHow we knowReport a problem
Codes
What other systems call epacadostat · ClinicalTrials.gg INT000589
- MeSH (NLM) C000613752epacadostatOne source NLM
- UNII (FDA) 71596A9R13EPACADOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q126607104EpacadostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C92582EpacadostatOne source FDA
- DrugBank DB11717One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613752 | epacadostat | One source NLM |
| UNII (FDA) | 71596A9R13 | EPACADOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q126607104 | Epacadostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C92582 | Epacadostat | One source FDA |
| DrugBank | DB11717 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.